Nvidia Invests $2B in CoreWeave, Price Target Raised to $110
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.INVESTMENT:Nvidiaand CoreWeaveannounced an expansion of their relationship to enable CoreWeave to accelerate the buildout of more than five gigawatts of AI factories by 2030. In addition, Nvidia has invested $2B in CoreWeave Class A common stock at a purchase price of $87.20 per share. The companies intend to: build AI factories developed and operated by CoreWeave using Nvidia's computing platform technology to meet customer demand; accelerate CoreWeave's procurement of land, power and shell to build AI factories; test and validate CoreWeave's AI-native software and reference architecture, including SUNK and CoreWeave Mission Control; deploy multiple generations of Nvidia infrastructure across CoreWeave's platform through early adoption of Nvidia computing architectures, including the Rubin platform, Vera CPUs and Bluefield storage systems.COMPUTE DEMAND:DA Davidson upgraded CoreWeave to Buy from Neutral with a price target of $110, up from $68, after assuming coverage of the name. The firm cites strengthening compute demand for the upgrade. CoreWeave has "multiple de-risking pathways" in 2026 with favorable upside potential relative to the downside risk that is already priced into the shares, the analyst tells investors in a research note. DA believes CoreWeave shares are unlikely to sustainably move higher without a "de-risking event that would significantly reduce" its "perceived counterparty risk and capital-structure overhang." The probability of these events "increases materially" in 2026, contends the firm.PREMIUM PRICES:OpenAI is targeting about $60 per 1,000 views for ChatGPT ads, on par with live NFL broadcasts and above Meta's sub-$20 cost-per-thousand impressions, while offering little conversion data, The Information's Ann Gehan and Catherine Perloff.MAIA 200:Microsoft'sScott Guthrie, Executive Vice President, Cloud + AI, stated in a blog, "Today, we're proud to introduce Maia 200, a breakthrough inference accelerator engineered to dramatically improve the economics of AI token generation. Maia 200 is an AI inference powerhouse: an accelerator built on TSMC's 3nm process with native FP8/FP4 tensor cores, a redesigned memory system with 216GB HBM3e at 7 TB/s and 272MB of on-chip SRAM, plus data movement engines that keep massive models fed, fast and highly utilized. This makes Maia 200 the most performant, first-party silicon from any hyperscaler, with three times the FP4 performance of the third generation Amazon Trainium, and FP8 performance above Google's seventh generation TPU. Maia 200 is also the most efficient inference system Microsoft has ever deployed, with 30% better performance per dollar than the latest generation hardware in our fleet today. Maia 200 is part of our heterogenous AI infrastructure and will serve multiple models, including the latest GPT-5.2 models from OpenAI, bringing performance per dollar advantage to Microsoft Foundry and Microsoft 365 Copilot. The Microsoft Superintelligence team will use Maia 200 for synthetic data generation and reinforcement learning to improve next-generation in-house models... Maia 200 is deployed in our US Central datacenter region near Des Moines, Iowa, with the US West 3 datacenter region near Phoenix, Arizona, coming next and future regions to follow. Maia 200 integrates seamlessly with Azure, and we are previewing the Maia SDK with a complete set of tools to build and optimize models for Maia 200."AI USED IN TRIALS:AI has begun helping drug companies progress through trials and regulatory submissions, Maggie Fick and Michael Erman of Reuters. AI is assisting with finding participants and clinical trial sites as well as drafting documents for regulators. Many drugmakers, including Eli Lillyhave entered partnerships with Nvidia, hoping AI will also improve the success rate of new drugs. Other drug companies in the space also using AI include Novartis, GSK, Genmab, and Teva Pharmaceutical.
